SA517390509B1 - مركب مشتق ثلاثي الحلقات، وطريقة لتحضيره ، وتركيبة صيدلانية تشتمل عليه - Google Patents
مركب مشتق ثلاثي الحلقات، وطريقة لتحضيره ، وتركيبة صيدلانية تشتمل عليهInfo
- Publication number
- SA517390509B1 SA517390509B1 SA517390509A SA517390509A SA517390509B1 SA 517390509 B1 SA517390509 B1 SA 517390509B1 SA 517390509 A SA517390509 A SA 517390509A SA 517390509 A SA517390509 A SA 517390509A SA 517390509 B1 SA517390509 B1 SA 517390509B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- same
- tricyclic derivative
- tankyrase
- pharmaceutical composition
- derivative compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 2
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 abstract 2
- 101710129670 Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 abstract 2
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 abstract 2
- 101710129674 Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 abstract 2
- 230000003287 optical effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150081021 | 2015-06-09 | ||
| PCT/KR2016/005911 WO2016200101A2 (ko) | 2015-06-09 | 2016-06-03 | 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA517390509B1 true SA517390509B1 (ar) | 2021-06-02 |
Family
ID=57503424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA517390509A SA517390509B1 (ar) | 2015-06-09 | 2017-12-07 | مركب مشتق ثلاثي الحلقات، وطريقة لتحضيره ، وتركيبة صيدلانية تشتمل عليه |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10464919B2 (https=) |
| EP (1) | EP3312177B1 (https=) |
| JP (2) | JP2018521033A (https=) |
| KR (1) | KR101837047B1 (https=) |
| CN (1) | CN107849040B (https=) |
| AU (1) | AU2016276806B9 (https=) |
| BR (1) | BR112017026392B1 (https=) |
| CA (1) | CA2990277C (https=) |
| CL (1) | CL2017003138A1 (https=) |
| DK (1) | DK3312177T3 (https=) |
| ES (1) | ES2870203T3 (https=) |
| MX (1) | MX375707B (https=) |
| MY (1) | MY194590A (https=) |
| NZ (1) | NZ738187A (https=) |
| PH (1) | PH12017502228B1 (https=) |
| PL (1) | PL3312177T3 (https=) |
| PT (1) | PT3312177T (https=) |
| RU (1) | RU2715413C2 (https=) |
| SA (1) | SA517390509B1 (https=) |
| WO (1) | WO2016200101A2 (https=) |
| ZA (1) | ZA201708663B (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20180252A1 (es) | 2015-06-09 | 2018-02-02 | Bayer Pharma AG | Moduladores alostericos positivos del receptor muscarinico m2 |
| MX375707B (es) * | 2015-06-09 | 2025-03-06 | Onconic Therapeutics Inc | Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo. |
| KR101775356B1 (ko) | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
| CN109689654A (zh) | 2016-07-11 | 2019-04-26 | 拜耳医药股份有限公司 | 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途 |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| CN108727377A (zh) * | 2017-04-14 | 2018-11-02 | 四川大学 | 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途 |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| US20220110936A1 (en) * | 2019-02-02 | 2022-04-14 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof |
| EP3953360B1 (en) * | 2019-04-09 | 2024-02-28 | F. Hoffmann-La Roche AG | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
| SI3999506T1 (sl) | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| MX2022001200A (es) * | 2019-07-29 | 2022-02-21 | Jeil Pharmaceutical Co Ltd | Metodo para el tratamiento de accidente cerebrovascular usando un derivado triciclico. |
| US20220324899A1 (en) * | 2019-08-14 | 2022-10-13 | Metro International Biotech, Llc | Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide |
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| AU2020372682A1 (en) * | 2019-10-31 | 2022-06-09 | Jd Bioscience Inc. | Tricyclic compound and pharmaceutical use thereof |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| GB202012969D0 (en) * | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
| CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
| US11591331B2 (en) | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| EP4328224A4 (en) * | 2021-04-22 | 2025-06-18 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | PARP INHIBITOR WITH PIPERAZINE STRUCTURE, MANUFACTURING METHOD THEREOF AND PHARMACEUTICAL USE THEREOF |
| WO2022222966A1 (zh) * | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
| CN115702156A (zh) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| EP4342470A4 (en) * | 2021-05-18 | 2025-04-30 | Onconic Therapeutics Inc. | THERAPEUTIC AGENT FOR PARP INHIBITOR-RESISTANT CANCER |
| MX2023013624A (es) * | 2021-05-18 | 2023-11-30 | Onconic Therapeutics Inc | Forma cristalina del compuesto derivado triciclico, metodo para preparar la misma y composicion farmaceutica que comprende la misma. |
| MA63136A1 (fr) * | 2021-05-18 | 2024-06-28 | Onconic Therapeutics Inc. | Agent thérapeutique contre le cancer résistant à un inhibiteur de parp |
| WO2023011608A1 (zh) * | 2021-08-05 | 2023-02-09 | 上海枢境生物科技有限公司 | 含三并环类衍生物调节剂、其制备方法和应用 |
| AU2022334408A1 (en) | 2021-08-27 | 2024-02-15 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| CN118119618A (zh) * | 2021-09-09 | 2024-05-31 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| KR102867210B1 (ko) | 2021-10-01 | 2025-10-14 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
| WO2023061406A1 (zh) * | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| US20250163022A1 (en) * | 2021-12-22 | 2025-05-22 | Synnovation Therapeutics, Inc. | Parp1 inhibitors |
| KR20240134366A (ko) * | 2022-01-13 | 2024-09-09 | 에이스랜드 테라퓨틱스 (홍콩) 리미티드 | 피페라진 고리 함유 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 용도 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| CN119013279A (zh) * | 2022-03-11 | 2024-11-22 | 上海瑛派药业有限公司 | 作为parp抑制剂的取代的三环类化合物及其应用 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| AU2023259236B2 (en) | 2022-04-28 | 2025-01-09 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| JP7835895B2 (ja) * | 2022-05-07 | 2026-03-25 | サイブランチ セラピューティクス カンパニー リミテッド | Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体 |
| CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| WO2024041608A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂的晶体形式及其用途 |
| CN119677736A (zh) * | 2022-08-24 | 2025-03-21 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途 |
| WO2024099416A1 (zh) * | 2022-11-10 | 2024-05-16 | 上海海和药物研究开发股份有限公司 | 一种稠合三环类parp1抑制剂、其制备方法及用途 |
| WO2024255697A1 (zh) * | 2023-06-13 | 2024-12-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391554A (en) * | 1992-09-09 | 1995-02-21 | Warner-Lambert Company | Dihydro- and tetrahydronaphthyridines |
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| DE102004028973A1 (de) | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| BRPI0719123A2 (pt) * | 2006-09-01 | 2013-12-17 | Cylene Pharmaceuticals Inc | Moduladores de serina-treonina proteína cinase e parp |
| US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| KR101179753B1 (ko) * | 2007-11-06 | 2012-09-04 | 제일약품주식회사 | 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물 |
| AU2009314760B2 (en) * | 2008-11-11 | 2011-11-10 | Je Il Pharmaceutical Co.,Ltd | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
| KR101827444B1 (ko) | 2012-02-01 | 2018-02-08 | 제일약품주식회사 | 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법 |
| MX375707B (es) * | 2015-06-09 | 2025-03-06 | Onconic Therapeutics Inc | Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo. |
| KR101775356B1 (ko) * | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
-
2016
- 2016-06-03 MX MX2017016013A patent/MX375707B/es active IP Right Grant
- 2016-06-03 PH PH1/2017/502228A patent/PH12017502228B1/en unknown
- 2016-06-03 BR BR112017026392-0A patent/BR112017026392B1/pt active IP Right Grant
- 2016-06-03 KR KR1020160069199A patent/KR101837047B1/ko active Active
- 2016-06-03 WO PCT/KR2016/005911 patent/WO2016200101A2/ko not_active Ceased
- 2016-06-03 AU AU2016276806A patent/AU2016276806B9/en active Active
- 2016-06-03 JP JP2017564557A patent/JP2018521033A/ja not_active Ceased
- 2016-06-03 NZ NZ738187A patent/NZ738187A/en unknown
- 2016-06-03 MY MYPI2017704653A patent/MY194590A/en unknown
- 2016-06-03 CA CA2990277A patent/CA2990277C/en active Active
- 2016-06-03 ES ES16807741T patent/ES2870203T3/es active Active
- 2016-06-03 US US15/579,692 patent/US10464919B2/en active Active
- 2016-06-03 DK DK16807741.0T patent/DK3312177T3/da active
- 2016-06-03 RU RU2017146130A patent/RU2715413C2/ru active
- 2016-06-03 PT PT168077410T patent/PT3312177T/pt unknown
- 2016-06-03 PL PL16807741T patent/PL3312177T3/pl unknown
- 2016-06-03 CN CN201680040992.8A patent/CN107849040B/zh active Active
- 2016-06-03 EP EP16807741.0A patent/EP3312177B1/en active Active
-
2017
- 2017-12-07 SA SA517390509A patent/SA517390509B1/ar unknown
- 2017-12-07 CL CL2017003138A patent/CL2017003138A1/es unknown
- 2017-12-19 ZA ZA2017/08663A patent/ZA201708663B/en unknown
-
2019
- 2019-05-09 JP JP2019088851A patent/JP6806969B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA517390509B1 (ar) | مركب مشتق ثلاثي الحلقات، وطريقة لتحضيره ، وتركيبة صيدلانية تشتمل عليه | |
| PH12017501921A1 (en) | Novel compounds | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| NZ742742A (en) | Compositions and methods for inhibiting arginase activity | |
| TW201613901A (en) | New compounds | |
| PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| WO2016130920A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| PH12017500810A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| IL261196A (en) | A pharmaceutical preparation for cancer, containing a polyphenol compound as an active ingredient | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| EA202191548A1 (ru) | Ингибиторы плазменного калликреина человека | |
| MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| WO2016187620A3 (en) | Anti-cancer compounds | |
| MX2018002177A (es) | Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo. | |
| MX2021005273A (es) | Inhibidores de quinasa rock. | |
| UA115010C2 (uk) | Застосування фармацевтичної композиції для профілактики та лікування хвороб, обумовлених підвищеним рівнем індуцибельної синтази оксиду азоту | |
| GB2553685A (en) | Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis | |
| EA202091668A3 (ru) | Ингибиторы калликреина плазмы человека |